This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, M. E. Articles by Harrison, D. G. Search for Related Content PubMed PubMed Citation Articles by Davis, M. E. Articles by Harrison, D. G. Related Collections Pathophysiology Lipid and lipoprotein metabolism Endothelium/vascular type/nitric oxide Mechanism of atherosclerosis/growth factors

(Circulation. 2001;103:2.)
© 2001 American Heart Association, Inc.

Editorials

Cracking Down on Caveolin: Role of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Modulating Edothelial Cell Nitric Oxide Production

Michael E. Davis; David G. Harrison

From the Department of Medicine, Emory University School of Medicine, and Veterans Administration Hospital, Atlanta, Ga.

Correspondence to David G. Harrison, Professor of Medicine, Emory University School of Medicine, Cardiology Department, 1639 Pierce Drive, WMB-319, Atlanta, GA 30322. E-mail dharr02@emory.edu

Key Words: Editorials • statins • lipoproteins • cholesterol

One of the most effective approaches in the treatment of atherosclerosis has been the use of 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) to treat hypercholesterolemia. During the past decade, numerous studies involving >20 000 individuals have shown that these drugs dramatically reduce cardiovascular death, myocardial infarction, unstable angina, and stroke. Statin therapy prevents events in individuals with established cardiovascular disease and is also effective in primary prevention.¹

A major mechanism by which lipid lowering is thought to improve outcome is by preventing the development of new atherosclerotic lesions and by depleting lipids from established plaques (ie, plaque stabilization).^{2 3} A striking finding is that statins seem to decrease clinical events within a few months of the onset of therapy.⁴ This suggests that they may have beneficial effects beyond those of plaque stabilization and lesion prevention.

One such beneficial effect might be the restoration of nitric oxide production by the endothelium. Endothelium-derived nitric oxide, previously known as the endothelium-derived relaxing factor, modulates vasodilatation and prevents platelet adhesion, the expression of adhesion molecules, and smooth muscle cell proliferation.⁵ Nitric oxide has also been shown to have antioxidant effects by enhancing the expression of superoxide dismutase,⁶ preventing lipid-chain reactions,⁷ and reacting with the superoxide anion.⁵ Thus, nitric oxide seems to play a major role as an endogenous protective factor against atherosclerosis. Indeed, virtually every atherosclerosis risk factor is associated with decreased endothelial cell nitric oxide production, and it is likely that this loss of nitric oxide is a major reason why these conditions predispose to . . . [Full Text of this Article]

This article has been cited by other articles:

				D.D. Waters and K.K. Khush Management of the acute coronary syndrome patient Eur. Heart J. Suppl., July 1, 2004; 6(suppl_C): C49 - C57. [Abstract] [Full Text] [PDF]

				F. R. DANESH and Y. S. KANWAR Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy FASEB J, May 1, 2004; 18(7): 805 - 815. [Abstract] [Full Text] [PDF]

				S. Tsimikas and J. L. Witztum Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2122 - 2124. [Full Text] [PDF]

				Z. A. Massy and C. Guijarro Statins: effects beyond cholesterol lowering Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1738 - 1741. [Full Text] [PDF]